In November 2012 over 250 delegates participated in the 3rd Annual World Orphan Drug Congress Europe. This event covers strategies and opportunities from Clinical Development and R&D, Market Access, Pricing & Reimbursement , Corporate Development and Drug Repositioning & Indication Expansion. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Ri De Ridder, Director General, National Institute for Health & Disability Insurance.
This presentation covers the following key points:
â¢ A national take on pricing and reimbursement for rare disease treatments
â¢ Economics of treating rare diseases: should orphan drugs even be treated differently when talking price?
â¢ What would be the wider cost of ignoring the rare disease problem?
â¢ While prices are high, how much of healthcare budget is spent of orphan drugs?
Why not check out our eBook, showcasing the best presentations from the 2012 event. Download a copy here >
The 4th World Orphan Drugs Congress Europe is a content packed, 2 day event with 2 dedicated tracks and is taking place this year in November. For more information about the event, please visit the website >